Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-09-23 8:56 pm Purchase |
2024-09-16 | 13D | Zenas BioPharma, Inc. ZBIO |
SR ONE CAPITAL MANAGEMENT LLC | 4,911,539 12.300% |
4,911,539 (New Position) |
Filing History |
| 2024-07-08 8:54 pm Purchase |
2024-06-28 | 13D | Kala Pharmaceuticals, Inc. KALA |
SR ONE CAPITAL MANAGEMENT LLC | 445,643 9.990% |
445,643 (New Position) |
Filing History |
| 2024-03-25 6:41 pm Sale |
2024-03-21 | 13D | Arcellx, Inc. ACLX |
SR ONE CAPITAL MANAGEMENT LLC | 2,346,630 4.440% |
-800,000 (-25.42%) |
Filing History |
| 2024-02-09 8:14 pm Sale |
2023-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
SR ONE CAPITAL MANAGEMENT LLC | 0 0.000% |
-272,885 (Position Closed) |
Filing History |
| 2023-12-18 4:16 pm Sale |
2023-12-14 | 13D | Arcellx, Inc. ACLX |
SR ONE CAPITAL MANAGEMENT LLC | 3,146,630 6.460% |
-800,000 (-20.27%) |
Filing History |
| 2023-06-02 4:46 pm Sale |
2023-05-31 | 13D | Arcellx, Inc. ACLX |
SR ONE CAPITAL MANAGEMENT LLC | 3,946,630 8.220% |
-540,544 (-12.05%) |
Filing History |
| 2023-05-19 5:02 pm Sale |
2023-05-11 | 13D | Arcellx, Inc. ACLX |
SR ONE CAPITAL MANAGEMENT LLC | 4,487,174 9.350% |
-1,012,833 (-18.42%) |
Filing History |
| 2022-06-27 4:35 pm Unchanged |
2022-06-21 | 13D | Arcellx, Inc. ACLX |
SR ONE CAPITAL MANAGEMENT LLC | 5,500,007 12.900% |
0 (Unchanged) |
Filing History |
| 2022-02-17 12:46 pm Purchase |
2022-02-08 | 13D | Arcellx, Inc. ACLX |
SR ONE CAPITAL MANAGEMENT LLC | 5,500,007 15.800% |
5,500,007 (New Position) |
Filing History |
| 2022-02-11 8:35 pm Purchase |
2021-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
SR ONE CAPITAL MANAGEMENT LLC | 272,885 16.900% |
272,885 (New Position) |
Filing History |